Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 4/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.68 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290469 | 1.00 | AKR1C1 (1.00) | AKR1C1AKR1C3AKR1C2PTGS2KMT2A | |
| SCHEMBL39275 | 1.00 | AKR1C1 (1.00) | AKR1C1AKR1C3AKR1C2PTGS2KMT2A | |
| SCHEMBL27448137 | 0.98 | AKR1C1 (0.96) | AKR1C1AKR1C3AKR1C2PTGS2KMT2A | |
| Benzophenone SCHEMBL28139683 | 0.94 | AKR1C1 (0.88) | AKR1C1AKR1C3AKR1C2PTGS2KMT2A | |
| Ethylene Glycol SCHEMBL27995732 | 0.92 | AKR1C1 (0.85) | AKR1C1AKR1C3AKR1C2PTGS2KMT2A | |
| Alcohol SCHEMBL27937505 | 0.90 | AKR1C1 (0.81) | AKR1C1AKR1C3AKR1C2PTGS2KMT2A | |
| SCHEMBL9298399 | 0.90 | AKR1C1 (0.81) | AKR1C1AKR1C3AKR1C2PTGS2KMT2A | |
| SCHEMBL1416571 | 0.90 | AKR1C1 (0.81) | AKR1C1AKR1C3AKR1C2PTGS2KMT2A | |
| Methacrylic Acid SCHEMBL1838687 | 0.89 | AKR1C1 (0.79) | AKR1C1AKR1C3AKR1C2PTGS2KMT2A | |
| SCHEMBL13092046 | 0.88 | AKR1C1 (0.78) | AKR1C1AKR1C3AKR1C2PTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874466-A | N, N-dimethylamide compound and synthesis method thereof | 海南大学 | 2025-04-25 | — | — | CN | claimed |
| EP-2042168-B1 | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2013-10-23 | — | — | EP | claimed |
| EP-1427386-B1 | PRODUCTS FOR PREVENTING PENETRATION INTO THE SKIN | YISSUM RES DEV CO (IL) | 2010-10-20 | — | — | EP | claimed |
| US-7736630-B2 | Products for preventing penetration into the skin | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2010-06-15 | — | — | US | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| EP-1425001-B1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-20070037874-A1 | Manufacturing process of isoflavan or isoflavene derivatives | BICBIO CO., LTD. (KR) | 2007-02-15 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-6916890-B1 | Thermally reworkable epoxy resins and compositions based thereon | HENKEL CORPORATION (US) | 2005-07-12 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| WO-2005037815-A1 | A MANUFACTURING PROCESS OF ISOFLAVAN OR ISOFLAVENE DERIVATIVES | BICBIO CO., LTD. (KR) | 2005-04-28 | — | — | WO | claimed |
| US-4356247-A | LITHOGRAPHY; PRINTING PLATES; PHOTORESISTS; HIGH-SPEED SENSITIZERS; SOTRAGE STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1982-10-26 | — | — | US | claimed |
| US-20260044082-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2026-02-12 | — | — | US | disclosed |
| US-4247597-A | Electroscopic carrier particles having a carboxylic acid surface treatment | PITNEY BOWES, INC. (US) | 1981-01-27 | — | — | US | disclosed |
| US-4067857-A | Polyester catalyst system comprising an antimony-containing polycondensation catalyst and an ethylenically unsaturated compound and process employing same | STAUFFER CHEMICAL COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037874-A1 | Manufacturing process of isoflavan or isoflavene derivatives | CYP51A1, CYP2E1, CYP2F1 | AKR1C1 190/4885AKR1C3 291/4885AKR1C2 221/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | AKR1C1 2043/4885AKR1C3 1660/4885AKR1C2 2523/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | AKR1C1 2446/4885AKR1C3 3104/4885AKR1C2 2236/4885 |
| US-20260044082-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | MMS19, PARG, EPCAM | AKR1C1 3275/4885AKR1C3 3434/4885AKR1C2 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.